EUFOREA consensus on biologics for CRSwNP with or without asthma

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of pati...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Allergy (Copenhagen) Ročník 74; číslo 12; s. 2312 - 2319
Hlavní autori: Fokkens, Wytske J., Lund, Valerie, Bachert, Claus, Mullol, Joaquim, Bjermer, Leif, Bousquet, Jean, Canonica, Giorgio W., Deneyer, Lauren, Desrosiers, Martin, Diamant, Zuzana, Han, Joseph, Heffler, Enrico, Hopkins, Claire, Jankowski, Roger, Joos, Guy, Knill, Andrew, Lee, Jivianne, Lee, Stella E., Mariën, Gert, Pugin, Benoit, Senior, Brent, Seys, Sven F., Hellings, Peter W.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Denmark Blackwell Publishing Ltd 01.12.2019
Wiley
John Wiley and Sons Inc
Predmet:
Allergies
Allergology
Asthma
Asthma - complications
Biological products
Biological Products - administration & dosage
Biological Products - adverse effects
Biological Products - therapeutic use
biologics
Chronic Disease
chronic rhinosinusitis
Clinical Decision-Making
Clinical Medicine
Comorbidity
Disease Management
Health Services Needs and Demand
Human health and pathology
Humans
Immunoglobulin E
Immunology
Immunotherapy
Interleukin 5
Klinisk medicin
Life Sciences
Lungmedicin och allergi
Medical and Health Sciences
Medicin och hälsovetenskap
Mucosa
nasal polyps
Nasal Polyps - complications
Polyps
Pulmonology and respiratory tract
Respiratory diseases
Respiratory Medicine and Allergy
Respiratory tract diseases
Review
Reviews
Rhinitis
Rhinitis - complications
Rhinitis - drug therapy
Rhinosinusitis
Sinusitis
Sinusitis - complications
Sinusitis - drug therapy
Treatment Outcome
type 2 inflammation
chronic rhinosinusitis
nasal polyps
asthma
biologics
type 2 inflammation
ISSN:0105-4538, 1398-9995, 1398-9995
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-News-1
ObjectType-Review-5
ObjectType-Feature-4
ObjectType-Conference-2
content type line 23
ObjectType-Article-3
ISSN:0105-4538
1398-9995
1398-9995
DOI:10.1111/all.13875